Glioma targeted therapy: insight into future of molecular approaches

K Yang, Z Wu, H Zhang, N Zhang, W Wu, Z Wang… - Molecular Cancer, 2022 - Springer
Gliomas are the common type of brain tumors originating from glial cells. Epidemiologically,
gliomas occur among all ages, more often seen in adults, which males are more susceptible …

The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease

V Rothhammer, FJ Quintana - Nature Reviews Immunology, 2019 - nature.com
The environment, diet, microbiota and body's metabolism shape complex biological
processes in health and disease. However, our understanding of the molecular pathways …

Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma

G Agliardi, AR Liuzzi, A Hotblack, D De Feo… - Nature …, 2021 - nature.com
Glioblastoma multiforme (GBM) is the most common and aggressive form of primary brain
cancer, for which effective therapies are urgently needed. Chimeric antigen receptor (CAR) …

Targeting immunosuppressive adenosine in cancer

D Vijayan, A Young, MWL Teng, MJ Smyth - Nature Reviews Cancer, 2017 - nature.com
Despite the success of anti-programmed cell death protein 1 (PD1), anti-PD1 ligand 1
(PDL1) and anti-cytotoxic T lymphocyte antigen 4 (CTLA4) therapies in advanced cancer, a …

ATP and cancer immunosurveillance

O Kepp, L Bezu, T Yamazaki, F Di Virgilio… - The EMBO …, 2021 - embopress.org
While intracellular adenosine triphosphate (ATP) occupies a key position in the bioenergetic
metabolism of all the cellular compartments that form the tumor microenvironment (TME) …

Big opportunities for small molecules in immuno-oncology

JL Adams, J Smothers, R Srinivasan… - Nature reviews Drug …, 2015 - nature.com
The regulatory approval of ipilimumab (Yervoy) in 2011 ushered in a new era of cancer
immunotherapies with durable clinical effects. Most of these breakthrough medicines are …

Immunosuppressive activities of adenosine in cancer

B Allard, PA Beavis, PK Darcy, J Stagg - Current opinion in pharmacology, 2016 - Elsevier
Highlights•Adenosine protects tissues against excessive inflammation and promotes tissue
repair.•The adenosine pathway is hijacked to dampen anti-tumor immunity.•Targeting CD73 …

Anti-CD73 in cancer immunotherapy: awakening new opportunities

L Antonioli, GG Yegutkin, P Pacher, C Blandizzi… - Trends in cancer, 2016 - cell.com
Over recent years, significant advances in cancer immunotherapy have been made due to a
better understanding of the principles underlying tumor biology and immunology. In this …

Immunological metagene signatures derived from immunogenic cancer cell death associate with improved survival of patients with lung, breast or ovarian …

AD Garg, D De Ruysscher, P Agostinis - Oncoimmunology, 2016 - Taylor & Francis
The emerging role of the cancer cell-immune cell interface in sha** tumorigenesis/
anticancer immunotherapy has increased the need to identify prognostic biomarkers …

Targeting the CD73-adenosine axis in immuno-oncology

D Allard, P Chrobak, B Allard, N Messaoudi, J Stagg - Immunology letters, 2019 - Elsevier
The ectonucleotidases CD39 and CD73 are cell surface enzymes that catabolize the
breakdown of extracellular ATP into adenosine. As such, they constitute critical components …